This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints, Permissions and Rights Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kars, M. Articles by Pereira, A. M. Search for Related Content PubMed PubMed Citation Articles by Kars, M. Articles by Pereira, A. M. Related Collections Neuroendocrinology and Pituitary Cardiovascular Endocrinology

Aortic Valve Calcification and Mild Tricuspid Regurgitation But No Clinical Heart Disease after 8 Years of Dopamine Agonist Therapy for Prolactinoma

Departments of Endocrinology and Metabolic Diseases (M.K., J.W.A.S., J.A.R., A.M.P.) and Cardiology (V.D., E.R.H., J.J.B.), Leiden University Medical Center, 2300 RC Leiden, The Netherlands; and Department of Internal Medicine (R.A.F.), Section of Endocrinology, Erasmus Medical Center, 3000 DR Rotterdam, The Netherlands

Address all correspondence and requests for reprints to: M. Kars, M.D., Department of Endocrinology and Metabolic Diseases, C4-R, Leiden University Medical Center, P.O. Box 9600, 2300 RC Leiden, The Netherlands. E-mail: m.kars{at}lumc.nl.

Objective: Treatment with ergot-derived dopamine agonists, pergolide, and cabergoline has been associated with an increased frequency of valvular heart disease in Parkinson’s disease. The aim of the present study was to assess the prevalence of valvular heart disease in patients treated with dopamine agonists for prolactinomas.

Design: This was a cross-sectional study.

Patients: We performed two-dimensional and Doppler echocardiography in 78 consecutive patients with prolactinoma (mean age 47 ± 1.4 yr, 26% male, 31% macroprolactinoma) treated with dopamine agonists for at least 1 yr (mean 8 ± 0.6 yr) and 78 control subjects. Patients were classified according to treatment: patients treated with cabergoline (group 1: n = 47) and patients not treated with cabergoline (group 2: n = 31).

Results: Clinically relevant valvular heart disease was present in 12% of patients (nine of 78) vs. 17% of controls (13 of 78) (P = 0.141) and 17% (eight of 47) of patients treated with cabergoline vs. 3% (one of 31) of patients not treated with cabergoline (P = 0.062). Mild tricuspid regurgitation was present in 41% of patients vs. 26% of controls (P = 0.042), and aortic valve calcification was present in 40% of patients, compared with 18% of controls (P = 0.003). There was no relation between the cumulative dose of cabergoline and the presence of mild, moderate, or severe valve regurgitation.

Conclusion: Several years of dopamine agonist treatment in patients with prolactinomas is associated with increased prevalence of aortic valve calcification and mild tricuspid regurgitation but not with clinically relevant valvular heart disease. Therefore, additional studies on the adverse cardiac effects of dopaminergic drugs in prolactinoma are warranted, especially in patients with much longer use of these drugs.

This article has been cited by other articles:

				C. Busso, M. Fernandez-Sanchez, J. A. Garcia-Velasco, J. Landeras, A. Ballesteros, E. Munoz, S. Gonzalez, C. Simon, J.-C. Arce, and A. Pellicer The non-ergot derived dopamine agonist quinagolide in prevention of early ovarian hyperstimulation syndrome in IVF patients: a randomized, double-blind, placebo-controlled trial Hum. Reprod., February 6, 2010; (2010) deq005v1. [Abstract] [Full Text] [PDF]

				O. M. Dekkers, J. Lagro, P. Burman, J. O. Jorgensen, J. A. Romijn, and A. M. Pereira Recurrence of Hyperprolactinemia after Withdrawal of Dopamine Agonists: Systematic Review and Meta-Analysis J. Clin. Endocrinol. Metab., January 1, 2010; 95(1): 43 - 51. [Abstract] [Full Text] [PDF]

				J. Kharlip, R. Salvatori, G. Yenokyan, and G. S. Wand Recurrence of Hyperprolactinemia after Withdrawal of Long-Term Cabergoline Therapy J. Clin. Endocrinol. Metab., July 1, 2009; 94(7): 2428 - 2436. [Abstract] [Full Text] [PDF]

				S. Droogmans, D. Kerkhove, B. Cosyns, and G. Van Camp Role of echocardiography in toxic heart valvulopathy Eur J Echocardiogr, June 1, 2009; 10(4): 467 - 476. [Abstract] [Full Text] [PDF]

				S. Melmed, A. Colao, A. Barkan, M. Molitch, A. B. Grossman, D. Kleinberg, D. Clemmons, P. Chanson, E. Laws, J. Schlechte, et al. Guidelines for Acromegaly Management: An Update J. Clin. Endocrinol. Metab., May 1, 2009; 94(5): 1509 - 1517. [Abstract] [Full Text] [PDF]

				M. Sherlock, A. A Toogood, and R. Steeds Dopamine agonist therapy for hyperprolactinaemia and cardiac valve dysfunction; a lot done but much more to do Heart, April 1, 2009; 95(7): 522 - 523. [Full Text] [PDF]

				N. M Martin, T. Tan, and K. Meeran Dopamine agonists and hyperprolactinaemia BMJ, March 3, 2009; 338(mar03_3): b381 - b381. [Full Text]

				M. E. Molitch The Cabergoline-Resistant Prolactinoma Patient: New Challenges J. Clin. Endocrinol. Metab., December 1, 2008; 93(12): 4643 - 4645. [Full Text] [PDF]

				E. R. Smith, J. Loeffler, M. Misra, S. R. Pomerantz, A. Stemmer-Rachamimov, and M. D. Post Case 37-2008 -- A 17-Year-Old Boy with a Pituitary Tumor and Skull Abnormalities N. Engl. J. Med., November 27, 2008; 359(22): 2367 - 2377. [Full Text] [PDF]